Published By : 04 Dec 2017 | Published By : QYRESEARCH
The dengue vaccine that has been administered to several children in Philippines could make the situation worse. As such, the officials have now stopped the programme at the end of the previous week. More than 730,000 children aged 9 or older hailing from the three of the most dengue-affected regions received a dose of the vaccine.
Mosquitoes are a Threat Worldwide
Dengvaxia, as the vaccine is called has been analyzed by Sanofi Pasteur, a France-based manufacturer. The analysis discovers that in the long-term dengue infected people who have received this drug is more likely to suffer from severe cases of dengue than those patients who have not been administered the vaccine. The analysis of the vaccine was based on six years of clinical data.
Mosquitoes are a threat worldwide and are responsible for many fatalities that are linked to dengue. Dengue is a mosquito borne disease that results in acute flu-like symptoms. In more acute cases of dengue, organ failure, breathing problems, and hemorrhaging can happen.
According to World Health Organization (WHO) every year around 96 million people get infected with dengue. In an effort to eliminate dengue, the health department of Philippines has launched this public immunization drive that is worth US$69.5 mn. It is the first such programme of its kind in the world.
However, earlier the drug was declared as a critical one in its fight against dengue by the same manufacturer, Sanofi.
Nevertheless, health secretary of the department of Health, Fransisco Duque III, said that there have been no cases of severe infection of dengue amongst those who have been vaccinated with this drug and the government would increase its mechanisms of surveillance.